These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7640231)

  • 1. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.
    Gooding R; Riches P; Dadian G; Moore J; Gore M
    Br J Cancer; 1995 Aug; 72(2):452-5. PubMed ID: 7640231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells.
    Zorn U; Dallmann I; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Cytokine; 1994 Jul; 6(4):358-64. PubMed ID: 7948742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
    Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
    Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 regulation of soluble IL-2 receptor levels following thermal injury.
    Teodorczyk-Injeyan JA; Sparkes BG; Lalani S; Peters WJ; Mills GB
    Clin Exp Immunol; 1992 Oct; 90(1):36-42. PubMed ID: 1382903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
    Damle RN; Advani SH; Gangal SG
    Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid.
    Miossec P; Elhamiani M; Edmonds-Alt X; Sany J; Hirn M
    Arthritis Rheum; 1990 Nov; 33(11):1688-94. PubMed ID: 2242065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
    Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
    Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
    Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
    Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].
    Akiyama K; Tsuji M; Kurokawa Y; Yokota K; Kojima K; Naruo S; Kanayana HO; Kagawa S
    Nihon Hinyokika Gakkai Zasshi; 1997 Apr; 88(4):473-8. PubMed ID: 9155114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
    Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
    Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
    Bodey B; Psenko V; Lipsey AL; Kaiser HE
    Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the participation of interleukin-2 (IL-2) and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin.
    Hassuneh MR; Nagarkatti PS; Nagarkatti M
    Blood; 1997 Jan; 89(2):610-20. PubMed ID: 9002965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15.
    Treiber-Held S; Stewart DM; Barraclough HA; Kurman CC; Nelson DL
    Clin Immunol Immunopathol; 1996 Jul; 80(1):67-75. PubMed ID: 8674241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro.
    Pizzolo G; Vincenzi C; Vinante F; Rigo A; Veneri D; Chilosi M; Dusi S; Poli G; Zambello R; Semenzato G
    Cell Immunol; 1992 Apr; 141(1):253-9. PubMed ID: 1555253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.
    Symons JA; Wood NC; Di Giovine FS; Duff GW
    J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
    Dummer R; Posseckert G; Nestle F; Witzgall R; Burger M; Becker JC; Schäfer E; Wiede J; Sebald W; Burg G
    J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.